Researchers who follow their instincts and achieve slow results while trying to break barriers have little support. They replace it with persistence. This is the story of Katalin Karikó and Drew Weissman. What was once a dream in their minds was later a success. Their work together for decades was essential to achieving mRNA vaccines, and their perseverance was rewarded today with the 2023 Nobel Prize in Medicine. Read More
Researchers from Longhorn Vaccines & Diagnostics LLC recently presented preclinical data for the novel unconjugated peptide vaccine LHNVD-201, which is being developed as a universal vaccine candidate for protection against different strains of influenza and COVID-19. Read More
Psoriasis is an autoimmune disorder characterized by abnormal differentiation of keratinocytes and chronic inflammation where current treatments frequently are associated with severe side effects. Read More
The U.S. Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), has awarded up to $37 million in funding to the Thymus Rejuvenation project, led by Thymmune Therapeutics Inc. Read More
Shenzhen Targetrx Biotechnology Co. Ltd. has disclosed cycloalkyl or heterocyclyl substituted heteroaryl compounds acting as Bruton tyrosine kinase (BTK) and BTK (C481S mutant) inhibitors reported to be useful for the treatment of cancer, inflammation, allergy and autoimmune disease. Read More
The calcineurin inhibitor tacrolimus is an immunosuppressive drug frequently used to prevent transplant rejection in solid organ transplant patients. Tacrolimus acts by suppressing T-cell activity within and around the transplanted organ. However, this drug also inhibits T-cell function in the skin, contributing to a high incidence of skin cancer among transplant recipients. Read More
The FDA has cleared IND applications for UBT-251 injection, a long-acting triple-targeted glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP)/glucagon receptor agonist developed by The United Bio-Technology (Hengqin) Co. Ltd., a wholly owned subsidiary of The United Laboratories International Holdings Ltd., for adult type 2 diabetes and for overweight or obese subjects. Read More
Researchers from Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have synthesized son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous syndrome and Noonan syndrome. Read More
Hangzhou Bio Sincerity Pharmaceutical Technology Co. Ltd. has identified histamine H3 receptor antagonists reported to be useful for the treatment of pain, attention deficit hyperactivity disorder, schizophrenia, epilepsy, sleep disorders, obesity, eating disorder, neuropathic pain and itching. Read More
Glycyrrhizic acid (GL) and its glycocan display anti-inflammatory, antiviral and antioxidant properties. Highly conserved nuclear protein (HMGB1) is a pro-inflammatory mediator that can be inhibited by GL, but the large size of the latter creates the need to obtain GL analogues with enhanced activity and stability. Read More
Shanghai Yingli Pharmaceutical Co. Ltd. has described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer. Read More
Fudan University has patented compounds acting as microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) inhibitors and proprotein convertase subtilisin/kexin-type 9 (PCSK9) degradation inducers reported to be useful for the treatment of alopecia, atherosclerosis, cancer, Alzheimer’s disease, pulmonary fibrosis, hyperlipidemia, keratosis and obesity, among others. Read More
Researchers from Zhengzhou University have reported the discovery of lysine-specific histone demethylase 1A (LSD1) inhibitors as potential immune response enhancers for the treatment of gastric cancer. Read More
